v3.26.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
3 Months Ended
Jul. 28, 2023
Mar. 31, 2026
Dec. 31, 2025
Retained Earnings (Accumulated Deficit)   $ (1,062,238) $ (1,082,015)
Cash, Cash Equivalents, and Short-Term Investments   572,800  
Commercialization Agreement With Neuraxpharm [Member]      
License and Collaboration Agreements, One-time, Non-refundable Payment $ 140,000 $ 204,900